Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. Francisco Robert-Vizcarrondo

Dr. Francisco Robert-Vizcarrondo

Medical Oncologist

Dr. Francisco Robert-Vizcarrondo is a senior scientist and professor of hematology/oncology at the University of Alabama-Birmingham School of Medicine.

Get in touch
Jump to a Topic:

About Francisco Robert-Vizcarrondo

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Research Excellence icon

    Excellence in Research

  • 30+ Years of Experience icon

    30+ Years of Experience

  • Board Certified icon

    Board Certified in Medical Oncology

Robert-Vizcarrondo has been part of the Alabama-Birmingham School of Medicine and the O’Neal Comprehensive Cancer Center since 1990, playing a major role in the Experimental Therapeutics division.

The O’Neal Cancer Center is the only one in the state with a National Cancer Institute designation. It has become well known for its early-detection initiatives and cutting-edge research.

There currently are more than 200 active clinical trials at the O’Neal Center, where 400 physician/scientists see 5,000 new cancer patients annually.

Robert-Vizcarrondo has also served for almost three decades as chief of the Hematology/Oncology Section at the Department of Veterans Affairs Medical Center in Birmingham.

Researching New Cancer Drugs

Much of Robert-Vizcarrondo’s research focus has involved non-small cell lung cancer and drug development for early phases of various cancers. He is known for advancing the treatment of thoracic malignancies such as lung cancer and pleural mesothelioma.

For example, he co-authored a pilot study of zoledronic acid for previously treated patients with advanced pleural mesothelioma. The 2017 study proved no significant toxicity from the drug and modest clinical activity.

In 2019, he published a study at the UAB Medical Center detailing the synergy between the drugs nintedanib and bevacizumab when used on patients with advanced solid tumors.

Education, Affiliations and Recognition

Robert-Vizcarrondo received his degree from the University of Puerto Rico School of Medicine, where he also completed an internship and a residency. He earned a postdoctoral fellowship from the University of Alabama-Birmingham Hospital in 1976.

He has been part of the American Association for Cancer Research since 2000. His other professional affiliations include the International Association for the Study of Lung Cancer and the American Society of Clinical Oncology.

Robert-Vizcarrondo is certified in medical oncology, hematology and internal medicine. He has received a “Top Doctors in America” and “Top Doctors in Cancer” designation several times from Castle Connolly.

Disclaimer: Dr. Francisco Robert-Vizcarrondo has no professional affiliation with

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Daniel King, Content Writer for
Edited by

2 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Jamil, M. (2017, March 9). A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma.
    Retrieved from:
  2. UAB Medicine. (n.d.). About Francisco Robert-Vizcarrondo. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified August 2, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now